Heparin, bivalirudin, or the best of both for STEMI interventions.
Ian C GilchristPublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2019)
Whether heparin, bivalirudin, or bivalirudin delivered on the background of prior heparin therapy, during primary PCI therapy is associated with a better outcome is difficult to ascertain from any one study. Meta-analysis of available trials suggests that the use of bivalirudin on top of prior heparin therapy may be associated with the lowest all-cause mortality and major adverse cardiovascular events while preserving much of the access site bleeding reduction of bivalirudin alone. There may be a role for initial therapy of STEMI with a broad-spectrum anticoagulant such as heparin that is then focused to a more specific direct-thrombin inhibitor (bivalirudin) in primary PCI.
Keyphrases
- percutaneous coronary intervention
- coronary artery disease
- venous thromboembolism
- st segment elevation myocardial infarction
- st elevation myocardial infarction
- cardiovascular events
- acute coronary syndrome
- acute myocardial infarction
- antiplatelet therapy
- coronary artery bypass grafting
- atrial fibrillation
- growth factor
- emergency department
- cardiovascular disease
- coronary artery bypass
- heart failure
- stem cells